# Telix Pharmaceuticals Ltd

Summary updated: 2026-10-02T13:44:50.233345Z
Canonical: https://finbar.com/research/companies/telix-pharmaceuticals-ltd

## Overview

Telix Pharmaceuticals Ltd is a radiopharmaceutical company focused on developing and commercialising targeted imaging and therapeutic products for cancer care. Its business spans precision-medicine diagnostics, therapeutic research and development, and manufacturing and supply-chain services; its stated purpose is to “redefine cancer care.” [1](https://telixpharma.com/our-company/) [2](https://app.finbar.com/go?id=T17471727)

Telix’s operations span Australia, North America, Europe and Asia-Pacific. For the year ended 31 December 2025, it reported US$803.8 million in revenue from customers; in the first half of 2026, it reported US$477 million in revenue. [3](https://app.finbar.com/go?id=T17471661) [4](https://app.finbar.com/go?id=T17471728) [5](https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/)
[2](https://app.finbar.com/go?id=T17471727)[3](https://app.finbar.com/go?id=T17471661)[4](https://app.finbar.com/go?id=T17471728)[1](https://telixpharma.com/our-company/)[5](https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/)

## Products & services

Telix’s commercial imaging products include Illuccix and Gozellix, gallium-68-labelled PSMA PET agents used in prostate cancer imaging to help locate lesions and inform clinical decisions. Gozellix is described as a next-generation cold kit for preparing PSMA-PET imaging. The 2025 report records US approval of Gozellix and Illuccix registrations in multiple EU countries. [6](https://app.finbar.com/go?id=P151948434)[7](https://app.finbar.com/go?id=P151952436)[8](https://app.finbar.com/go?id=P151948994)[9](https://app.finbar.com/go?id=P151949186)[10](https://app.finbar.com/go?id=P151953131)

Other imaging products remain candidates rather than reported marketed products. Zircaix (TLX250-Px; ⁸⁹Zr-DFO-girentuximab) is a PET candidate for characterizing renal masses as clear-cell renal cell carcinoma, while Pixclara (TLX101-Px; ¹⁸F-FET) is a radiolabelled amino-acid PET agent for glioma imaging. The report notes FDA complete response letters for both candidates. [11](https://app.finbar.com/go?id=P151949365)[12](https://app.finbar.com/go?id=P151949561)[10](https://app.finbar.com/go?id=P151953131)

Telix’s therapeutic pipeline includes TLX591-Tx for prostate cancer, TLX250-Tx for kidney cancer and TLX101-Tx for glioma. TLX250-Tx is described as a ¹⁷⁷Lu-DOTA-girentuximab radiopharmaceutical conjugate candidate; TLX101-Tx (iodofalan-¹³¹I) is a brain-cancer candidate. The report does not identify these as marketed products. [13](https://app.finbar.com/go?id=P151948319)[14](https://app.finbar.com/go?id=P151948794)[15](https://app.finbar.com/go?id=P151949315)[16](https://app.finbar.com/go?id=P151949496)

Services include distribution through the RLS radiopharmacy network, which handles PET, SPECT and therapeutic radiopharmaceuticals; RLS revenue includes distribution-service fees and PET/SPECT product sales. The 2025 report records US$803.794 million in revenue from contracts with customers, but does not disclose brand-level revenue or product-mix percentages. [17](https://app.finbar.com/go?id=P151950685)[18](https://app.finbar.com/go?id=P151952673)[19](https://app.finbar.com/go?id=P151952456)
[6](https://app.finbar.com/go?id=P151948434)[7](https://app.finbar.com/go?id=P151952436)[8](https://app.finbar.com/go?id=P151948994)[9](https://app.finbar.com/go?id=P151949186)[10](https://app.finbar.com/go?id=P151953131)[11](https://app.finbar.com/go?id=P151949365)[12](https://app.finbar.com/go?id=P151949561)[13](https://app.finbar.com/go?id=P151948319)[14](https://app.finbar.com/go?id=P151948794)[15](https://app.finbar.com/go?id=P151949315)[16](https://app.finbar.com/go?id=P151949496)[17](https://app.finbar.com/go?id=P151950685)[18](https://app.finbar.com/go?id=P151952673)[19](https://app.finbar.com/go?id=P151952456)

## Geographic presence

Telix’s commercial footprint spans multiple regions: its Q1 2026 update said Illuccix had launched in 21 countries, including 16 in Europe. The company also identified active commercial launches in the U.K., Germany, France, Finland, Sweden, Norway and Denmark in an October 2025 update. These launch figures describe market presence, not the distribution of sales. [20](https://telixpharma.com/news-views/q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement/)[21](https://telixpharma.com/news-views/telix-reports-us206m-revenue-fy-2025-guidance-upgraded/)

At year-end 2025, Telix reported non-current assets located in the U.S. (US$481.2 million), Australia (US$101.8 million), Canada (US$86.6 million), Belgium (US$59.5 million), the U.K. (US$37.1 million) and other countries (US$8.2 million). The U.S. represented approximately 62% of the reported total; this is an asset-location measure, not revenue. The FY2025 filing did not report revenue by customer geography. [22](https://app.finbar.com/go?id=T17471735)[23](https://app.finbar.com/go?id=P151955594)

The company’s manufacturing and supply-chain footprint includes sites or operations in Brussels South, Seneffe, North Melbourne, Sacramento, Vancouver and Yokohama, as well as U.S. RLS radiopharmacies. Telix lists its headquarters in Melbourne and offices in Tokyo, Indianapolis, Sacramento, Angleton, Brussels, Liège and Vancouver. [2](https://app.finbar.com/go?id=T17471727)[24](https://app.finbar.com/go?id=P151955561)[25](https://telixpharma.com/telix-manufacturing-solutions/)[26](https://telixpharma.com/contact/)
[22](https://app.finbar.com/go?id=T17471735)[23](https://app.finbar.com/go?id=P151955594)[2](https://app.finbar.com/go?id=T17471727)[24](https://app.finbar.com/go?id=P151955561)[20](https://telixpharma.com/news-views/q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement/)[21](https://telixpharma.com/news-views/telix-reports-us206m-revenue-fy-2025-guidance-upgraded/)[25](https://telixpharma.com/telix-manufacturing-solutions/)[26](https://telixpharma.com/contact/)

## Business segments

Telix reports three business segments: **Precision Medicine**, focused on commercial sales and development of diagnostic products, including International and Medical Technologies; **Therapeutics**, covering its therapeutic pipeline and related pre-commercial licence and R&D-service revenue; and **Manufacturing Solutions**, its manufacturing and supply-chain business. [2](https://app.finbar.com/go?id=T17471727)

In the 2025 annual report, external revenue was approximately **77.4% Precision Medicine** (US$621.930m), **1.2% Therapeutics** (US$9.273m), and **21.5% Manufacturing Solutions** (US$172.591m), out of US$803.794m total revenue from customers. [4](https://app.finbar.com/go?id=T17471728) The latest available report as of October 2, 2026 is the H1 2026 interim report; it reports Precision Medicine revenue of US$388.6m and Manufacturing Solutions third-party product and service sales of US$88.7m. [27](https://telixpharma.com/wp-content/uploads/2026/08/H1-2026-Interim-Report.pdf)
[2](https://app.finbar.com/go?id=T17471727)[2](https://app.finbar.com/go?id=T17471727)[2](https://app.finbar.com/go?id=T17471727)[4](https://app.finbar.com/go?id=T17471728)[4](https://app.finbar.com/go?id=T17471728)[4](https://app.finbar.com/go?id=T17471728)[4](https://app.finbar.com/go?id=T17471728)[27](https://telixpharma.com/wp-content/uploads/2026/08/H1-2026-Interim-Report.pdf)

## Company history

Telix Pharmaceuticals was founded in 2015 by Christian Behrenbruch and Andreas Kluge, and became a public unlisted company in January 2017. That month it raised seed funding and licensed Heidelberg Pharma’s girentuximab program; later in 2017, it raised A$50 million in an initial public offering and listed on the ASX. [28](https://telixpharma.com/wp-content/uploads/2022/10/Telix-Annual-Report-for-year-ended-31-December-2019.pdf) [29](https://telixpharma.com/wp-content/uploads/2023/01/TLX_Appendix_4E_and_2017_Annual_Report.pdf) [30](https://asxonline.com/content/asxonline/public/notices/2017/nov/1290.17.11.html)

In 2018, Telix expanded its prostate-cancer therapeutic program through the acquisition of Atlab Pharma and broadened its radiopharmaceutical operations by acquiring ANMI; it also established a Japanese subsidiary. In 2019, it agreed to acquire a licensed radiopharmaceutical production facility in Belgium, extending its European manufacturing presence. [31](https://telixpharma.com/news-views/strategy-update-acceleration-of-prostate-cancer-therapy-program/) [32](https://app.finbar.com/go?id=P151950458) [33](https://telixpharma.com/news-views/telix-pharmaceuticals-establishes-japanese-subsidiary-appoints-key-executives/) [34](https://telixpharma.com/news-views/telix-pharmaceuticals-to-acquire-european-production-facility/)

A major commercial milestone came in 2021, when Illuccix was approved in Australia and the United States for prostate-cancer imaging; U.S. commercial orders began in 2022. In 2024, Telix expanded through acquisitions of IsoTherapeutics, ARTMS and QSAM Biosciences, adding development, isotope-production and therapeutic-platform capabilities. [35](https://telixpharma.com/news-views/australian-tga-approves-illuccix-for-prostate-cancer-imaging/) [36](https://telixpharma.com/news-views/fda-approves-telixs-prostate-cancer-imaging-product-illuccix/) [37](https://telixpharma.com/news-views/commercial-launch-illuccix-now-available-to-order-in-the-united-states/) [38](https://telixpharma.com/news-views/telix-completes-acquisition-of-isotherapeutics/) [39](https://telixpharma.com/news-views/telix-completes-acquisition-of-artms-and-its-advanced-isotope-production-platform/) [40](https://telixpharma.com/news-views/telix-completes-acquisition-of-qsam-biosciences-and-its-bone-cancer-targeting-platform/)

In 2024, Telix ADSs began trading on Nasdaq, alongside its ASX listing. It completed the acquisition of U.S. radiopharmaceutical network RLS in January 2025, and subsequently received U.S. approval for its prostate-cancer imaging agent Gozellix and brain-cancer imaging drug Pixclara. [41](https://telixpharma.com/news-views/telix-adss-commence-trading-on-nasdaq/) [42](https://telixpharma.com/news-views/telix-completes-acquisition-of-rls-usa-inc/) [43](https://telixpharma.com/news-views/fda-approves-new-prostate-cancer-imaging-agent-gozellix/) [44](https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/)
[32](https://app.finbar.com/go?id=P151950458)[28](https://telixpharma.com/wp-content/uploads/2022/10/Telix-Annual-Report-for-year-ended-31-December-2019.pdf)[29](https://telixpharma.com/wp-content/uploads/2023/01/TLX_Appendix_4E_and_2017_Annual_Report.pdf)[30](https://asxonline.com/content/asxonline/public/notices/2017/nov/1290.17.11.html)[31](https://telixpharma.com/news-views/strategy-update-acceleration-of-prostate-cancer-therapy-program/)[33](https://telixpharma.com/news-views/telix-pharmaceuticals-establishes-japanese-subsidiary-appoints-key-executives/)[34](https://telixpharma.com/news-views/telix-pharmaceuticals-to-acquire-european-production-facility/)[35](https://telixpharma.com/news-views/australian-tga-approves-illuccix-for-prostate-cancer-imaging/)[36](https://telixpharma.com/news-views/fda-approves-telixs-prostate-cancer-imaging-product-illuccix/)[37](https://telixpharma.com/news-views/commercial-launch-illuccix-now-available-to-order-in-the-united-states/)[38](https://telixpharma.com/news-views/telix-completes-acquisition-of-isotherapeutics/)[39](https://telixpharma.com/news-views/telix-completes-acquisition-of-artms-and-its-advanced-isotope-production-platform/)[40](https://telixpharma.com/news-views/telix-completes-acquisition-of-qsam-biosciences-and-its-bone-cancer-targeting-platform/)[41](https://telixpharma.com/news-views/telix-adss-commence-trading-on-nasdaq/)[42](https://telixpharma.com/news-views/telix-completes-acquisition-of-rls-usa-inc/)[43](https://telixpharma.com/news-views/fda-approves-new-prostate-cancer-imaging-agent-gozellix/)[44](https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/)

## Sources

1. [telixpharma.com](https://telixpharma.com/our-company/)
2. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17471727)
3. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17471661)
4. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17471728)
5. [telixpharma.com](https://telixpharma.com/news-views/telix-2026-half-year-results-strong-commercial-execution-and-momentum-in-late-stage-pipeline/)
6. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151948434)
7. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151952436)
8. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151948994)
9. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151949186)
10. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151953131)
11. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151949365)
12. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151949561)
13. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151948319)
14. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151948794)
15. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151949315)
16. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151949496)
17. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151950685)
18. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151952673)
19. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151952456)
20. [telixpharma.com](https://telixpharma.com/news-views/q1-2026-strong-revenue-growth-and-therapeutics-pipeline-advancement/)
21. [telixpharma.com](https://telixpharma.com/news-views/telix-reports-us206m-revenue-fy-2025-guidance-upgraded/)
22. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=T17471735)
23. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151955594)
24. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151955561)
25. [telixpharma.com](https://telixpharma.com/telix-manufacturing-solutions/)
26. [telixpharma.com](https://telixpharma.com/contact/)
27. [telixpharma.com](https://telixpharma.com/wp-content/uploads/2026/08/H1-2026-Interim-Report.pdf)
28. [telixpharma.com](https://telixpharma.com/wp-content/uploads/2022/10/Telix-Annual-Report-for-year-ended-31-December-2019.pdf)
29. [telixpharma.com](https://telixpharma.com/wp-content/uploads/2023/01/TLX_Appendix_4E_and_2017_Annual_Report.pdf)
30. [asxonline.com](https://asxonline.com/content/asxonline/public/notices/2017/nov/1290.17.11.html)
31. [telixpharma.com](https://telixpharma.com/news-views/strategy-update-acceleration-of-prostate-cancer-therapy-program/)
32. [Telix Pharmaceuticals Ltd — Full financial report (2025 Y)](https://app.finbar.com/go?id=P151950458)
33. [telixpharma.com](https://telixpharma.com/news-views/telix-pharmaceuticals-establishes-japanese-subsidiary-appoints-key-executives/)
34. [telixpharma.com](https://telixpharma.com/news-views/telix-pharmaceuticals-to-acquire-european-production-facility/)
35. [telixpharma.com](https://telixpharma.com/news-views/australian-tga-approves-illuccix-for-prostate-cancer-imaging/)
36. [telixpharma.com](https://telixpharma.com/news-views/fda-approves-telixs-prostate-cancer-imaging-product-illuccix/)
37. [telixpharma.com](https://telixpharma.com/news-views/commercial-launch-illuccix-now-available-to-order-in-the-united-states/)
38. [telixpharma.com](https://telixpharma.com/news-views/telix-completes-acquisition-of-isotherapeutics/)
39. [telixpharma.com](https://telixpharma.com/news-views/telix-completes-acquisition-of-artms-and-its-advanced-isotope-production-platform/)
40. [telixpharma.com](https://telixpharma.com/news-views/telix-completes-acquisition-of-qsam-biosciences-and-its-bone-cancer-targeting-platform/)
41. [telixpharma.com](https://telixpharma.com/news-views/telix-adss-commence-trading-on-nasdaq/)
42. [telixpharma.com](https://telixpharma.com/news-views/telix-completes-acquisition-of-rls-usa-inc/)
43. [telixpharma.com](https://telixpharma.com/news-views/fda-approves-new-prostate-cancer-imaging-agent-gozellix/)
44. [telixpharma.com](https://telixpharma.com/news-views/fda-approves-telixs-brain-cancer-imaging-drug-pixclara/)

AI-generated summary; may contain errors. Not investment advice. Sign up to Finbar to view original document sources and access worldwide fundamental financial data and intelligence.